More evidence for the benefits of aggressive lipid-lowering with statins has come from the IDEAL study, which randomised nearly 9000 post-MI patients to either 80 mg of atorvastatin or 20/40 mg simvastatin daily. Terje Pedersen from Ulleval University Hospital in Norway presented the findings.
[audio:https://www.audiomedica.com/podcasting/aha2005/Terje_Pedersen.mp3]
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
